CytomX Therapeutics’ (CTMX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note published on Tuesday morning,Benzinga reports.

CytomX Therapeutics Price Performance

CTMX opened at $0.98 on Tuesday. The firm has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.17. CytomX Therapeutics has a 1 year low of $0.83 and a 1 year high of $5.85. The stock has a market cap of $76.91 million, a P/E ratio of 5.78 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. During the same quarter in the prior year, the firm posted $0.04 earnings per share. Equities analysts expect that CytomX Therapeutics will post -0.05 EPS for the current year.

Institutional Trading of CytomX Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE purchased a new position in shares of CytomX Therapeutics during the 3rd quarter valued at approximately $40,000. XTX Topco Ltd lifted its holdings in CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 48,033 shares in the last quarter. Forefront Analytics LLC lifted its holdings in CytomX Therapeutics by 206.7% during the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in shares of CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of CytomX Therapeutics during the third quarter worth about $104,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.